Navigation Links
Agendia Successfully Completes Bi-Annual FDA Inspection
Date:10/3/2011

IRVINE, California and AMSTERDAM, October 3, 2011 /PRNewswire/ --

Agendia, an innovative molecular cancer diagnostics company, today announced that the company successfully completed a recent, routine inspection of its Irvine, California-based laboratories by the US Food and Drug Administration (FDA). Agendia received FDA 510(k) clearance for its MammaPrint® breast cancer recurrence test in early 2007. It remains the first and only test of its kind to receive FDA clearance, which, in addition to validiation of the product's safety and efficacy, periodically subjects the company's laboratories to the scrutiny of FDA inspectors to ensure continuous compliance with regulations.

"Agendia was founded on the principle of providing safe and effective products to improve patients' quality of life, and we have gone to great lengths to ensure that MammaPrint meets this high standard," said Dr. Bernhard Sixt, CEO and co-founder of Agendia. "Ensuring the safety of MammaPrint doesn't just stop at the approval process.  We must ensure that MammaPrint continues to comply with regulations throughout the life of the test. This is why we sought FDA clearance and why we believe the industry, as a whole, should be regulated in the same manner. I am immensely proud that FDA has once again validated Agendia's MammaPrint test and take even greater pride to offer the only breast cancer recurrence test that has been subjected to such painstaking FDA oversight."

FDA inspectors thoroughly examined Agendia's facilities, evaluating the company's compliance with FDA's Good Manufacturing Practice Regulations (GMP), which require manufacturers of drugs, medical devices and FDA cleared laboratory tests to ensure product safety and effectiveness. GMP regulations compel companies, such as Agendia, to employ strong manufacturing practices that minimize or eliminate the risk of contamination, laboratory mixups and errors. FDA inspectors assessed Agendia's laboratory operations from top to bottom, including recordkeeping, personnel, sanitation and cleanliness, equipment, process validation and complaint handling. This meticulous inspection ensures the reliability and safety of Agendia's MammaPrint test, and protects patients.

About Agendia:

Agendia is a leading global commercial molecular diagnostic company that develops and markets genomic-based diagnostic products that improve the quality of life for cancer patients and simplifies complex treatment decisions for their physicians. Agendia's Symphony™ suite of breast cancer products is based on the analysis of hundreds of genes in a patient's breast and provides unprecedented biological insight to address complex treatment decisions. Symphony includes MammaPrint, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 expression assay, and TheraPrint®, a therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo or hormonal therapy, and which patients do not require these treatments and can instead be treated with other less arduous and costly methods.

In addition to the Symphony suite of tests, Agendia has a rich pipeline of genomic products in development based on its world-class genomic platform. The company also collaborates with pharmaceutical companies to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials.

Agendia was founded in 2003 as a spin-off of the Netherlands Cancer Institute and is based in Irvine, California, United States, and Amsterdam, the Netherlands. For more information, please visit http://www.agendia.com.


'/>"/>
SOURCE Agendia B.V.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Agendia Appoints New Chief Financial Officer
2. Agendias Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute - AVL
3. Agendia Appoints VP of Business Development
4. Agendia Publishes Direct Evidence That MammaPrint Predicts Benefit of Chemotherapy in Breast Cancer
5. Agendia Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervisory Board
6. Agendia Presents Data Supporting MammaPrints Predictive and Prognostic Power at 2009 St. Gallen Breast Cancer Conference
7. Agendia to Present at BioCenturys Future Leaders in the Biotech Industry Conference
8. Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting
9. Agendia Opens CLIA-Registered U.S. Genomics Laboratory
10. Agendia Supports Genentechs Citizens Petition Urging FDA to Hold In-Vitro Diagnostic Tests to One Set of Scientific and Regulatory Standards
11. Agendia Raises US $23 Million in Series E Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... Ken Hanson, a medical imaging research scientist ... have been selected as this year’s recipients of two top awards from SPIE, ... along with other honorees to accept their awards at a banquet in San Diego, ...
(Date:6/22/2017)... ... June 21, 2017 , ... Beaker, the industry’s ... in the life sciences industry, today announces a strategic partnership with Alcami Corporation, ... full advantage of Beaker’s expertise in executive recruitment solutions, providing Alcami with access ...
(Date:6/22/2017)... Germany (PRWEB) , ... June 22, 2017 , ... ... is taking over the allergy specialists DST Diagnostische Systeme & Technologien GmbH, thereby ... all know someone who suffers from hay fever, urticaria, asthma, atopic eczema or ...
(Date:6/22/2017)... ... June 22, 2017 , ... Tunnell ... the biopharma and life sciences industries, continue to be in demand for their ... Wolf will be speaking on “The State of Information Governance in the Biopharmaceutical ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, ... secure authentication solutions, today announced that it has ... Advanced Research Projects Activity (IARPA) to develop next-generation ... program. "Innovation has been a driving ... Thor program will allow us to innovate and ...
(Date:4/11/2017)... , April 11, 2017 No ... but researchers at the New York University Tandon ... of Engineering have found that partial similarities between ... systems used in mobile phones and other electronic ... The vulnerability lies in the fact ...
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
Breaking Biology News(10 mins):